Meeting
2023 ASCO Genitourinary Cancers Symposium
Cost-effectiveness analysis of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
Authors
Manish Kohli
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Manish Kohli , Maura Dougherty , Zachary Cutshall , Rylee Beckstead , Rhea Kohli , Benjamin Haaland , Richard Nelson , Minkyoung Yoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Other
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 268)
DOI
10.1200/JCO.2023.41.6_suppl.268
Abstract #
268
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormone-sensitive prostate cancer (mHSPC): A public payer perspective using network meta-analysis.
First Author: Manish Kohli
Poster
2020 Genitourinary Cancers Symposium
Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.
First Author: Neil Rohit Parikh
Poster
2024 ASCO Genitourinary Cancers Symposium
Molecular profiling and clinical relevance of low PTEN expression in patients with metastatic hormone-sensitive prostate cancer.
First Author: Marta Garcia de Herreros
Poster
2023 ASCO Genitourinary Cancers Symposium
Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting.
First Author: Terri Conner